2017
Janus Kinase Inhibitors
Kim A, Strober B. Janus Kinase Inhibitors. 2017, 187-198. DOI: 10.1007/978-3-319-66884-0_19.Peer-Reviewed Original ResearchAutoinflammatory disordersJanus kinase inhibitorNovel drug classJanus kinaseMedication classesAtopic dermatitisRheumatoid arthritisAlopecia areataHematologic disordersClinical dataDrug classesPolycythemia veraTherapeutic benefitJAK inhibitorsNew agentsJAK-STAT pathwayClinical useJakinibsKinase inhibitorsActivator of transcriptionDisordersPreliminary findingsSignal transducerInhibitorsHuman use
2007
The use of therapeutic interchange for biologic therapies.
Flood J, Mihalik C, Fleming R, Strober B, Zucker D, Burgoyne D. The use of therapeutic interchange for biologic therapies. Managed Care 2007, 16: 51-62. PMID: 17285813.Peer-Reviewed Original ResearchConceptsSelective serotonin reuptake inhibitorsProton pump inhibitorsBiologic agentsTherapeutic interchangeRheumatoid arthritisBiologic therapyHMG-CoA reductase inhibitorsSerotonin reuptake inhibitorsPopulation-based outcomesHealth care professionalsMode of administrationOverall treatment costsTolerability profileAppropriate therapyReuptake inhibitorsPsoriasis therapyPump inhibitorsDrug classesIndividual patientsCare professionalsNew agentsEnzyme inhibitorsPatientsReductase inhibitorsTherapy